home / stock / fwbi / fwbi news


FWBI News and Press, First Wave BioPharma Inc.

Stock Information

Company Name: First Wave BioPharma Inc.
Stock Symbol: FWBI
Market: NASDAQ

Menu

FWBI FWBI Quote FWBI Short FWBI News FWBI Articles FWBI Message Board
Get FWBI Alerts

News, Short Squeeze, Breakout and More Instantly...

FWBI - First Wave BioPharma changes name to Entero Therapeutics

2024-05-16 07:44:01 ET More on First Wave BioPharma First Wave Biopharma to raise about $4M of proceeds in direct offering Seeking Alpha’s Quant Rating on First Wave BioPharma Read the full article on Seeking Alpha For further details see: First Wa...

FWBI - First Wave BioPharma Changes Name to Entero Therapeutics

Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Ther...

FWBI - First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market

BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal...

FWBI - Expected US Company Earnings on Friday, May 10th, 2024

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

FWBI - First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointes...

FWBI - First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...

FWBI - BTTR, ICCM and SXTC among pre-market losers

2024-04-17 08:21:19 ET Losers: Arrowroot Acquisition Corp ( AILE ) -34% . Hub Cyber Security Ltd ( HUBC ) -22% . Longeveron ( LGVN ) -18% announces exercise of warrants for $6.2 Million gross proceeds . Sage Therapeutics SAGE -19% after mi...

FWBI - First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase

BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...

FWBI - First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference

BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...

FWBI - Expected US Company Earnings on Monday, April 1st, 2024

GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...

Next 10